<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00362427</url>
  </required_header>
  <id_info>
    <org_study_id>PR504</org_study_id>
    <nct_id>NCT00362427</nct_id>
  </id_info>
  <brief_title>Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®</brief_title>
  <official_title>A Randomized Trial to Assess the Immunogenicity and Safety of PR5I With an Adjuvant Composition Enhancement to the Hepatitis B Component and When Given Concomitantly With Prevnar®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      PR5I, a hexavalent pediatric combination vaccine is being developed to reduce the number of
      injections during the first 2 years of life while providing a complete course of immunization
      against infection caused by H. influenzae type b, hepatitis B virus, Corynebacterium
      diphtheriae, Clostridium tetani, Bordetella pertussis, and poliovirus types 1, 2, and 3.

      Primary Objective: To evaluate immunogenicity of PR5I with the adjuvant composition
      enhancement to the hepatitis B component when administered concomitantly with Prevnar®

      Secondary Objectives: To assess the safety and immunogenicity of PR5I when administered
      concomitantly, or one month apart with Prevnar® or separately with licensed vaccines used for
      routine infant vaccination in Canada.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide information concerning the immune response of subjects that received PR5I concomitantly with Prevnar</measure>
    <time_frame>14 Months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Polio</condition>
  <condition>Hepatitis B</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC</intervention_name>
    <description>0.5 mL, 4 doses, IM</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>PR5I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC</intervention_name>
    <description>0.5 Ml, 4 doses, IM</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>PR5I</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC</intervention_name>
    <description>0.5 mL, 4 doses, IM with concommitant vaccines</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>PR5I</other_name>
    <other_name>PENTACEL™</other_name>
    <other_name>NGERIX-B®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants aged 42 to 89 days inclusive on the day of inclusion.

          -  Born at full term of pregnancy (&gt;37 weeks).

          -  Informed consent form signed by the parent(s) or legally authorized representative.

          -  Able to attend all scheduled visits and to comply with the study procedures.

          -  Parent or legally authorized representative has access to a telephone.

          -  Parent or legally authorized representative able to read and write in English or
             French.

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the first trial
             vaccination.

          -  Planned participation in another clinical trial during the present trial period.

          -  Personal or immediate family history of congenital or acquired immunodeficiency,
             immunosuppressive therapy such as long-term systemic corticosteroids therapy.

          -  Known or suspected systemic hypersensitivity to any of the vaccine components or
             history of a life-threatening reaction to a vaccine containing the same substances as
             the trial vaccine(s).

          -  Chronic illness that could interfere with trial conduct or completion.

          -  Received blood or blood-derived products since birth.

          -  Any vaccination preceding the first trial vaccination or planned in the 4 weeks after
             any trial vaccination (flu vaccine may be given a minimum of 4 weeks prior to the
             first study vaccination).

          -  Previous vaccination with any acellular pertussis- (DTaP) or whole cell pertussis-
             (DTwP) based combination vaccines, Haemophilus influenzae type b (Hib)-conjugate,
             poliovirus, hepatitis B, or pneumococcal conjugate vaccines.

          -  Coagulation disorder contraindicating IM vaccination.

          -  Clinically significant findings on review of systems (determined by investigator or
             sub-investigator to be sufficient for exclusion).

          -  Developmental delay or neurological disorder.

          -  Any condition which, in the opinion of the investigator, would interfere with the
             evaluation of the vaccine or pose a health risk to the subject.

          -  Documented Hepatitis B surface Antigen (HBsAg) seropositivity in the child or his/her
             mother.

          -  History of Hib, hepatitis B, diphtheria, tetanus, pertussis or poliovirus disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Coquitlam</city>
        <state>British Columbia</state>
        <zip>V3C 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3R 8P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 3P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1S 0G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beauport</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3H 1P3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2006</study_first_submitted>
  <study_first_submitted_qc>August 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2006</study_first_posted>
  <last_update_submitted>January 10, 2014</last_update_submitted>
  <last_update_submitted_qc>January 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>H. influenzae type b</keyword>
  <keyword>Polio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

